Adicet Bio, Inc. (ACET) vs Champions Oncology, Inc. (CSBR)
A side-by-side comparison of Adicet Bio, Inc. and Champions Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACET
Adicet Bio, Inc.
$6.34HealthcareDelayed quote: Oct 6, 2026, 3:04 PM EDT
CSBR
Champions Oncology, Inc.
$4.90HealthcareDelayed quote: Oct 6, 2026, 2:48 PM EDT
Total return — ACET vs CSBR
growth of $100 · dividends reinvested · last 9yACET -99.7% (-46.8%/yr)CSBR +28.1% (+2.8%/yr)CSBR compounded faster over this window
Log scale — wide-divergence pair
ACET CSBR
ACET vs CSBR: by the numbers
- •CSBR is the larger company ($68M vs $59M market cap).
- •Both run net losses; ACET's is the smaller (0.00% vs -1.87% net margin).
Metrics side by side
Valuation
| Metric | ACET | CSBR |
|---|---|---|
| Forward P/E | N/A | 49.00 |
| P/S ratio | N/A | 1.12 |
| P/B ratio | 0.49 | 17.49 |
| EV / EBITDA | N/A | 256.67 |
Profitability
| Metric | ACET | CSBR |
|---|---|---|
| Gross margin | 0.00% | 49.30% |
| Operating margin | 0.00% | -1.72% |
| Net margin | 0.00% | -1.87% |
| ROE | -82.38% | -29.15% |
| ROIC | -79.68% | -6.75% |
Growth (annualized)
| Metric | ACET | CSBR |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.25% |
| Total return CAGR (5Y) | -44.24% | -13.07% |
Frequently asked
- How have ACET and CSBR total returns compared?
- Over the past 5 years, ACET delivered -44.24% and CSBR delivered -13.07% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.